Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1984 1
1987 4
1988 7
1989 3
1990 7
1991 8
1992 9
1993 9
1994 10
1995 15
1996 16
1997 22
1998 21
1999 20
2000 11
2001 18
2002 19
2003 24
2004 42
2005 32
2006 38
2007 43
2008 55
2009 56
2010 43
2011 46
2012 67
2013 93
2014 71
2015 86
2016 75
2017 80
2018 76
2019 91
2020 98
2021 89
2022 74
2023 96
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

1,460 results

Results by year

Filters applied: . Clear all
Page 1
Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment.
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Bahadoram S, et al. G Ital Nefrol. 2022 Jun 20;39(3):2022-vol3. G Ital Nefrol. 2022. PMID: 35819037 Free article. Review.
Renal cell carcinoma (RCC) is the most common type of urogenital cancer. ...The most common type of RCC, based on histological and molecular subtypes, is clear cell carcinoma which occurs frequently due to mutations in the VHL gene. ...
Renal cell carcinoma (RCC) is the most common type of urogenital cancer. ...The most common type of RCC, based on histo …
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
Jonasch E, Walker CL, Rathmell WK. Jonasch E, et al. Nat Rev Nephrol. 2021 Apr;17(4):245-261. doi: 10.1038/s41581-020-00359-2. Epub 2020 Nov 3. Nat Rev Nephrol. 2021. PMID: 33144689 Free PMC article. Review.
The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and progression are being increasingly defined. The TRACERx Renal studies and others that have described the interaction between tumour genomics and rem …
The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and progression are …
Modeling clear cell renal cell carcinoma and therapeutic implications.
Wolf MM, Kimryn Rathmell W, Beckermann KE. Wolf MM, et al. Oncogene. 2020 Apr;39(17):3413-3426. doi: 10.1038/s41388-020-1234-3. Epub 2020 Mar 2. Oncogene. 2020. PMID: 32123314 Free PMC article. Review.
Renal cell carcinoma (RCC) comprises a diverse group of malignancies arising from the nephron. The most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterized by genetic mutations in factors governing the …
Renal cell carcinoma (RCC) comprises a diverse group of malignancies arising from the nephron. The most prevalent type, …
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.
Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Makhov P, et al. Mol Cancer Ther. 2018 Jul;17(7):1355-1364. doi: 10.1158/1535-7163.MCT-17-1299. Mol Cancer Ther. 2018. PMID: 29967214 Free PMC article. Review.
Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors. ...
Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into various subtypes, with c …
What's new in the WHO 2022 classification of kidney tumours?
Alaghehbandan R, Siadat F, Trpkov K. Alaghehbandan R, et al. Pathologica. 2022 Feb;115(1):8-22. doi: 10.32074/1591-951X-818. Epub 2023 Jan 16. Pathologica. 2022. PMID: 36645398 Free PMC article. Review.
A major change in this edition is the grouping of renal tumours into broader categories that include "clear cell renal tumours", "papillary renal tumours", "oncocytic and chromophobe renal tumours", "collecting duct tumours" as wel …
A major change in this edition is the grouping of renal tumours into broader categories that include "clear cell ren …
Comprehensive review of chromophobe renal cell carcinoma.
Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Garje R, et al. Crit Rev Oncol Hematol. 2021 Apr;160:103287. doi: 10.1016/j.critrevonc.2021.103287. Epub 2021 Mar 19. Crit Rev Oncol Hematol. 2021. PMID: 33753250 Free article. Review.
Chromophobe renal cell carcinoma (chRCC) is the third most common type of RCC with distinct biology compared to other kidney cancer subtypes. ...ChRCC is characterized by chromosomal aneuploidy, TP53, PTEN, and mitochondrial gene mutations. Though the therape …
Chromophobe renal cell carcinoma (chRCC) is the third most common type of RCC with distinct biology compared to other k …
Grading of renal cell carcinoma.
Delahunt B, Eble JN, Egevad L, Samaratunga H. Delahunt B, et al. Histopathology. 2019 Jan;74(1):4-17. doi: 10.1111/his.13735. Histopathology. 2019. PMID: 30565310 Review.
Grading of renal cell carcinoma (RCC) has been recognised as a prognostic factor for almost 100 years. ...This grading system has been validated for both clear cell and papillary RCC. Validation studies for chromophobe RCC failed to demon …
Grading of renal cell carcinoma (RCC) has been recognised as a prognostic factor for almost 100 years. ...This grading …
Savolitinib: First Approval.
Markham A. Markham A. Drugs. 2021 Sep;81(14):1665-1670. doi: 10.1007/s40265-021-01584-0. Drugs. 2021. PMID: 34455538 Review.
Savolitinib (Orpathys(); HUTCHMED, AstraZeneca) is a receptor tyrosine kinase mesenchymal epithelial transition factor (MET) inhibitor being developed for the treatment of metastatic non-small cell lung cancer (NSCLC), papillary and clear cell renal …
Savolitinib (Orpathys(); HUTCHMED, AstraZeneca) is a receptor tyrosine kinase mesenchymal epithelial transition factor (MET) inhibitor being …
Metabolic reprogramming in clear cell renal cell carcinoma.
Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH. Wettersten HI, et al. Nat Rev Nephrol. 2017 Jul;13(7):410-419. doi: 10.1038/nrneph.2017.59. Epub 2017 May 8. Nat Rev Nephrol. 2017. PMID: 28480903 Review.
Research in many cancers has uncovered changes in metabolic pathways that control tumour energetics and biosynthesis, so-called metabolic reprogramming. Studies in clear cell renal cell carcinoma (ccRCC) have been particularly revealing, leading …
Research in many cancers has uncovered changes in metabolic pathways that control tumour energetics and biosynthesis, so-called metabolic re …
The immunology of renal cell carcinoma.
Díaz-Montero CM, Rini BI, Finke JH. Díaz-Montero CM, et al. Nat Rev Nephrol. 2020 Dec;16(12):721-735. doi: 10.1038/s41581-020-0316-3. Epub 2020 Jul 30. Nat Rev Nephrol. 2020. PMID: 32733094 Review.
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises several subtypes with unique characteristics. The most common subtype (~70% of cases) is clear-cell RCC. RCC is considered to be an immunogenic tumour but is known …
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises several subtypes with unique characte …
1,460 results